Clinical trial · Observational
Prognostic and Treatment-Response Factors in Metastatic Melanoma: Multi-Center Analysis
Evaluation of Clinical, Pathologic, and Molecular Determinants of Prognosis and Treatment Response in Patients With Metastatic Malignant Melanoma: A Multicenter Retrospective Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This multicenter, retrospective observational study aims to identify clinical, pathological, and molecular factors associated with prognosis and treatment response in patients with metastatic malignant melanoma. Medical records of adult patients diagnosed and treated between November 2022 and December 2024 at participating oncology centers in Türkiye were reviewed. Data collected include demographic features, disease characteristics, histopathologic findings, treatment modalities (immune checkpoint inhibitors, targeted therapy, or chemotherapy), and dermatologic adverse events. These variables will be analyzed in relation to survival outcomes to provide real-world evidence supporting personalized management strategies in metastatic melanoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Metastatic Malignant Melanoma | Melanoma | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Systemic Therapy for Metastatic Melanoma | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Multicenter Metastatic Melanoma Cohort
- description
- Includes adult patients diagnosed with metastatic malignant melanoma and treated between November 2022 and December 2024. Systemic therapies included immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab), BRAF/MEK targeted agents (dabrafenib, trametinib, vemurafenib, encorafenib, binimetinib), and chemotherapy (dacarbazine or temozolomide). Treatment was delivered per routine clinical practice; no experimental assignment occurred.
- interventionNames
- Drug: Systemic Therapy for Metastatic Melanoma
Primary outcomes (1)
- measure
- Progression-Free Survival (PFS)
- timeFrame
- From treatment initiation to disease progression or death, up to December 2024.
- description
- Progression-Free Survival (PFS) is defined as the time from initiation of systemic therapy to the earliest date of radiologically or clinically documented disease progression or death from any cause. Disease progression will be determined based on imaging studies or clinical evaluations recorded in medical files. Patients alive without documented progression at last follow-up will be censored.
Secondary outcomes (6)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥18 years * Histologically or cytologically confirmed metastatic malignant melanoma * Received ≥1 line of systemic therapy * Complete baseline and follow-up data * At least one measurable lesion or clinical response assessment * Managed between November 2022 - December 2024 at participating centers Exclusion Criteria: * Incomplete clinical or pathological data * Uncertain or revised diagnosis * Metastasis developing outside the inclusion window * Another primary malignancy (except allowed types) * Lost to follow-up before first response assessment
References
Publications (0)
Data not yet available